Best Genomics Companies in South Holland, Netherlands
The 30 best Genomics companies in South Holland, Netherlands in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Bluebee.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in South Holland
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Bluebee Provider of solutions for genomics data analysis | $13M | 127 mo ago | 31 | — | — | — | — |
| 2 | Amarna Therapeutics Developer of immune-modulating gene therapies for rare and prevalent autoimmune diseases and genetic diseases | $11M | 85 mo ago | 30 | Marjanne Messie CFO | CMS Made SimplePleskPHP+15 | 5 patents Patents concentrated in chemistry & materials | — |
| 3 | ProteoNic Provider of products and services for improving recombinant protein production levels | $8M | 181 mo ago | 20 | Frank Pieper CEO | WordPressMySQLPHP+23 | — | — |
| 4 | Facio Therapies Provider of small molecule therapeutics for Facioscapulohumeral Dystrophy | $3M | 133 mo ago | 7 | David Dasberg CEO | — | — | — |
| 5 | Genewity Biotech company focused on commercializing potentially groundbreaking therapies in the field of cell and gene… | $3M | 44 mo ago | — | Arno Bisschop Co-Founder & CEO | — | 2 patents Artificial thymus production for immune cell therapy and regenerative immunology | — |
| 6 | SkylineDX Provider of gene expression profiling tests for personalized medicine | $2M | 59 mo ago | 61 | Dharminder Chahal CEO | WordPressMySQLPHP+19 | 27 patents Predictive gene expression signatures for melanoma prognosis and therapy response | — |
| 7 | TherageniX Developer of non-viral delivery system for tissue regeneration | $1M | 38 mo ago | — | Anandkumar Nandakumar Co-Founder & CEO | — | — | — |
| 8 | GenomeScan Provider of next-generation genome sequencing and testing | $1M | 48 mo ago | 38 | Peter Belt CEO | WordPressMySQLPHP+28 | — | — |
| 9 | BaseClear Contract service laboratory with a focus on DNA technology, genomics and synthetic biology. | $1M | 87 mo ago | 96 | — | WordPress Block EditorCart FunctionalityWordPress+27 | — | — |
| 10 | 20Med Therapeutics Develops RNA-based therapeutics and vaccines for drug delivery | $736K | 42 mo ago | 13 | Michiel Lodder CEO | — | 15 patents Polymer-functionalized nanocarriers for gene and drug delivery applications | — |
| 11 | Amylon Developer of RNA therapeutics for rare beta-amyloid related diseases | $348K | 108 mo ago | 2 | Daniel de Boer Co-Founder | — | — | — |
| 12 | Imuno Therapeutics Developer of drug discovery and precision therapy platform for oncology | $340K | 60 mo ago | 5 | Jan Verhoef Founder | — | — | — |
Top 12 Genomics companies in South Holland
#1
Funding Raised · Leiden, South Holland · founded 2022$3.1Mraised▾
Biotech company focused on commercializing potentially groundbreaking therapies in the field of cell and gene therapies.
- Mar 2023Grant (prize money)$3.1M
#2
Funding Raised · The Hague, South Holland · founded 2022$1.2Mraised▾
Developer of non-viral delivery system for tissue regeneration. The company uses proprietary technology to deliver genes that can instruct the body to produce relevant proteins or factors that help in tissue regeneration.
- Sep 2023Grant (prize money)$1.2M
#3
Series A · Leiden, South Holland · founded 2008 · 30 employees$11Mraised▾
Developer of immune-modulating gene therapies for rare and prevalent autoimmune diseases and genetic diseases. Its proprietary platform includes SVac which is a viral vector used for the delivery of gene, prophylactic and therapeutic vaccines targeting indications such as allergies, autoimmune diseases, genetic disorders, cancer, and infectious diseases. It can be used for the treatment of AMD, HIV, Hepatitis, multiple sclerosis, and breast cancer.
- Oct 2019Series A$11M
#4
Acquired · Delft, South Holland · founded 2011 · 31 employees$13.3Mraised▾
Bluebee provides solutions for genomics data analysis to enable personalized medicine. The company provides a cloud-based platform to researchers and clinical labs to enable large-scale analysis of genomic data. Their proprietary algorithms provides next-gen sequencing analytics for alignment, and mapping and variant calling.
- Mar 2016Series A$11.3M
- May 2015Series A$1.9M
#5
Funding Raised · Leiden, South Holland · founded 2002 · 38 employees$1.2Mraised▾
Provider of next-generation genome sequencing and testing. The company is focusing on NGS genetic testing and diagnostics, exome sequencing, targeted disease panels, and research and development on genetic testing. The company is involved in finding disease causes using Next Generation Sequencing.
- Nov 2022Grant (prize money)$270.8K
- Jan 2020Grant (prize money)$312.9K
- Oct 2019Grant (prize money)$305K
- Jan 2017Grant (prize money)$336K
#6
Series A · South Holland · founded 2011 · 13 employees$735.8Kraised▾
Develops RNA-based therapeutics and vaccines for drug delivery. Its non-viral delivery platform is based on bioresponsive polymers designed for the intracellular delivery of oligonucleotides. The 20Med Nanoparticles are applicable for the delivery of oligonucleotide-based therapeutics. Its nanogel drug delivery platform provides protection of fragile payloads during administration and circulation but allows for a rapid bioresponsive release of that payload as the particles enter the cytosol. The bioresponsive polymeric nanoparticles can be loaded with oligonucleotides ranging from large plasmid DNAs (>12Kb) to small antisense oligos.
- May 2023Series A—
- Sep 2020Grant (prize money)$316.7K
- Nov 2017Seed—
- Jan 2017Grant (prize money)$419.1K
#7
Seed · Rotterdam, South Holland · founded 2005 · 61 employees$2.4Mraised▾
Provider of gene expression profiling tests for personalized medicine. Its proprietary platform Profiler includes a fully secure data analysis system for transcriptomics. Its lead product MMProfiler enables risk stratification of multiple myeloma patients by analyzing expression data of 92 clinically validated genes. It also has another product AML Profiler for subtyping acute myeloid leukemia varieties that is on the market. The company is developing another diagnostic tool for APprofiler for detection of angina pectoris.
- Dec 2021Seed—
- Jan 2020Grant (prize money)$280.5K
- Nov 2016Grant (prize money)$2.1M
- Oct 2016Grant (prize money)—
#8
Series A · Leiden, South Holland · founded 2007 · 20 employees$8.1Mraised▾
Provider of products and services for improving recombinant protein production levels. Its proprietary UNic technology is used to enhance the translation of messenger RNA (mRNA) by incorporating Translation enhancing elements in the expression vector, resulting in more protein per mRNA. This leads to significantly higher yields and greater manufacturing flexibility, with lower production costs. The company activities focus on industry-relevant fungal, yeast, plant, and mammalian expression hosts, for which it has developed platform-specific products and services. Services include molecular biology, vector construction, cell line, and production strain development.
- Sep 2011Series A$8.1M
#9
Series A · Leiden, South Holland · founded 2014 · 7 employees$3.1Mraised▾
Provider of small molecule therapeutics for Facioscapulohumeral Dystrophy. The disease is caused by the absence of repression of the DUX4 gene, causing accumulation of the unwanted DUX4 protein in the muscle cells leading to dystrophy. The company has developed a technology platform that enables high-throughput screening of compounds for their ability to repress the expression of DUX4 in primary cultures of muscle cells from FSHD patients.
- Oct 2015Series A$3.1M
#10
Funding Raised · Leiden, South Holland · founded 1993 · 96 employees$1.2Mraised▾
BaseClear is a contract research laboratory offering a suite of tailored services for metagenomics, genome analysis, microbial identification and typing, protein engineering and synthetic biology. It is using Next Generation Sequencing (NGS) technologies such as Illumina HiSEQ, MiSEQ and PacBio RS II platforms for metagenomics, genome analysis related projects. It also offers a wide range of bioinformatics solutions with a focus on NGS data analysis. In addition, it also provides a range of services in synthetic biology such as synthetic DNA libraries, custom cloning and others.
- Aug 2019Grant (prize money)$210.9K
- Jan 2019Grant (prize money)$162.1K
- Jan 2018Grant (prize money)$306.7K
- Dec 2016Grant (prize money)$544.5K
#11
Seed · Leiden, South Holland · founded 2023$20Kraised▾
Platform for gene editing applications and educational assistance in biological topics. It facilitates knowledge retrieval in biological domains, offering strategy prototyping for gene editing applications, and serving as an educational assistant for biological topics. The platform captures genetic and epigenetic information in a workflow to support the understanding of normal and disease biology. Its technology enables the phased reading of genetic and epigenetic data at a single-base resolution.
- 2024Seed$20K
#12
Seed · Leiden, South Holland · founded 2020 · 5 employees$340.3Kraised▾
Developer of drug discovery and precision therapy platform for oncology. The company has developed a proprietary technology platform to identify 3D models of neo-epitopes from the cell surface of a patient's tumor. This enables to the design of patient-specific immunotherapies.
- Nov 2021Seed$340.3K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising